Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?

Pharmacology and Therapeutics

Volumn 82, Issue 1, 1999, Pages 1-61

  Griebel, Guy ^a  

^a CNS Research Department   (France)

Author keywords

Anxiety disorders; Cholecystokinin; Corticotropin releasing factor; Natriuretic peptides; Tachykinins

Indexed keywords

2 BENZYL 1 (3,5 DIMETHYLBENZOYL) 4 (4 QUINOLINYLMETHYLAMINO)PIPERIDINE; ATRIAL NATRIURETIC FACTOR; BUSPIRONE; CHOLECYSTOKININ DERIVATIVE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CITALOPRAM; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DEVAZEPIDE; FLUOXETINE; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NATRIURETIC FACTOR; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ A; NEUROKININ B; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; NEUROPEPTIDE Y; PEPTIDE YY; QUIPAZINE; SAREDUTANT; SAUVAGINE; SUBSTANCE P; TACHYKININ; TETRAGASTRIN; UROTENSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY NEUROSIS; BEHAVIOR; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; TRANQUILIZING ACTIVITY;

ANIMALS; ANXIETY DISORDERS; CHOLECYSTOKININ; FORECASTING; HUMANS; LIGANDS; NEUROPEPTIDE Y; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECEPTORS, NEUROPEPTIDE; TACHYKININS;

EID: 0032977234     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(98)00041-2     Document Type: Review

References (343)

1. Aaron M.F., Lorenz C.M., Nemeroff C.B., Weiss J.M. CRF enhances fear and depresses behavioral activity following infusion into the parabrachial nucleus. Soc. Neurosci. Abstr. 17:1991;1417.
2. Abreu M.E., Conti L.H., Costello D.G., Enna S.J. Corticotropin-releasing factor (CRF) and depression. behavioral, hormonal and receptor changes in rats following chronic administration of CRF Clin. Neuropharmacol. 13(Suppl. 2):1990;245-246.
3. Adamec R.E., McKay D. The effects of CRF and α-helical CRF on anxiety in normal and hypophysectomized rats. J. Psychopharmacol. 7:1993;346-354.
4. Adamec R.E., Sayin U., Brown A. The effects of corticotrophin releasing factor (CRF) and handling stress on behavior in the elevated plus-maze test of anxiety. J. Psychopharmacol. 5:1991;175-186.
5. A receptors before and after the stress of predator exposure prevents lasting increases in anxiety-like behavior. implications for anxiety associated with posttraumatic stress disorder Behav. Neurosci. 111:1997;435-449.
6. B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J. Clin. Psychopharmacol. 15:1995;428-434.
7. Allen J.M., Gibson S.J., Adrian T.E., Polak J.M., Bloom S.R. Neuropeptide Y in human spinal cord. Brain Res. 308:1984;145-148.
8. Altemus M., Swedo S.E., Leonard H.L., Richter D., Rubinow D.R., Potter W.Z., Rapoport J.L. Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch. Gen. Psychiatry. 51:1994;794-803.
9. Aulisi E.F., Wehby R.G., Katz J.L., Valentino R.J. Selective proconflict effect of corticotropin-releasing factor (CRF). Soc. Neurosci. Abstr. 15:1989;1068.
10. Baldwin H.A., Rassnick S., Rivier J., Koob G.F., Britton K.T. CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology. 103:1991;227-232.
11. A receptor antagonist with anxiolytic-like activity in animal models. Br. J. Pharmacol. 121:1997;759-767.
12. Barradell L.B., Fitton A. Tandospirone. CNS Drugs. 5:1996;147-153.
13. Barrett J.E., Zhang L., Ahlers S.T., Wojnicki F.H. Acute and chronic effects of corticotropin-releasing factor on schedule-controlled responding and neurochemistry of pigeons. J. Pharmacol. Exp. Ther. 250:1989;788-794.
14. B antagonist LY 262691, LY 262684 and LY 247348 on punished responding of squirrel monkeys. Soc. Neurosci. Abstr. 17:1991;1063.
15. Becker L.A., Hennessy M.B. Further characterization of the behavioral effects of peripherally administered corticotropin-releasing factor in guinea pigs. Pharmacol. Biochem. Behav. 44:1993;925-930.
16. Behan D.P., Heinrichs S.C., Troncoso J.C., Liu X.J., Kawas C.H., Ling N., De Souza E.B. Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease. Nature. 378:1995;284-287.
17. Beinfeld M.C., Palkovits M. Distribution of cholecystokinin in the hypothalamus and the limbic system of the rat. Neuropeptides. 2:1981;123-129.
18. Belcheva I., Belcheva S., Petkov V.V., Petkov V.D. Asymmetry in behavioral responses to cholecystokinin microinjected into rat nucleus accumbens and amygdala. Neuropharmacology. 33:1994;995-1002.
19. B antagonist, reduces "state," but not "trait" anxiety in mice. Pharmacol. Biochem. Behav. 49:1994;433-436.
20. 2 receptors. Eur. J. Pharmacol. 272:1995;241-248.
21. 1 antagonist SR 140333 in the mouse black and white box model. Soc. Neurosci. Abstr. 21:1995;1696.
22. Berridge C.W., Dunn A.J. Corticotropin-releasing factor elicits naloxone sensitive stress-induced changes of exploratory behavior in mice. Regul. Pept. 16:1986;83-93.
23. Berridge C.W., Dunn A.J. A corticotrophin-releasing factor antagonist reverses the stress-induced change in exploratory behavior in mice. Hormon. Behav. 21:1987;393-401. a.
24. Berridge C.W., Dunn A.J. Corticotropin-releasing factor (CRF) and norepinephrine involvement in the regulation of exploratory behavior. Soc. Neurosci. Abstr. 13:1987;427. b.
25. Berridge C.W., Dunn A.J. CRF and restraint-stress decrease exploratory behavior in hypophysectomized mice. Pharmacol. Biochem. Behav. 34:1989;517-519.
26. Betancur C., Azzi M., Rostene W. Nonpeptide antagonists of neuropeptide receptors. tools for research and therapy Trends Pharmacol. Sci. 18:1997;372-386.
27. Bhattacharya S.K., Acharya S.B. Further investigations on the anxiogenic action of isatin. Biog. Amines. 9:1993;5-6.
28. Bhattacharya S.K., Mitra S.K., Acharya S.B. Anxiogenic activity of isatin, a putative biological factor, in rodents. J. Psychopharmacol. 5:1991;202-206.
29. Bhattacharya S.K., Chakrabarti A., Sandler M., Glover V. Anxiolytic activity of intraventricularly administered atrial natriuretic peptide in the rat. Neuropsychopharmacology. 15:1996;199-206. a.
30. Bhattacharya S.K., Chakrabarti A., Sandler M., Glover V. Effects of some anxiogenic agents on rat brain monoamine oxidase (MAO) A and B inhibitory (tribulin) activity. Indian J. Exp. Biol. 34:1996;1190-1193. b.
31. 125I-atrial natriuretic factor binding sites in the brain. Neuroendocrinology. 44:1986;365-372.
32. Bickerdike M.J., Marsden C.A. The anxiolytic profile of devazepide in the rat is abolished by isolation-rearing. J. Psychopharmacol. 8:1994;A47.
33. Bickerdike M.J., Marsden C.A., Dourish C.T., Fletcher A. The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze. Eur. J. Pharmacol. 271:1994;403-411.
34. Bidzseranova A., Gueron J., Toth G., Varga J., Telegdy G. Structure-activity studies on the effects of atrial natriuretic peptide, brain natriuretic peptide and their analogs on fear-motivated learning behavior in rats. Neuropeptides. 23:1992;61-65.
35. Billett E.A., Richter M.A., King N., Heils A., Lesch K.P., Kennedy J.L. Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene. Mol. Psychiatry. 2:1997;403-406.
36. Birnbaum S.G., Lidow M.S., Davis M. The effect of corticotropin releasing hormone on the acoustic startle reflex. Soc. Neurosci. Abstr. 21:1995;1697.
37. Bíró E., Sarnyai Z., Penke B., Szabo G., Telegdy G. Role of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral responses to cholecystokinin octapeptide sulfate ester in rats. Neuroendocrinology. 57:1993;340-345.
38. Bíró E., Toth G., Telegdy G. Involvement of neurotransmitters in the "anxiolytic-like" action of atrial natriuretic peptide in rats. Neuropeptides. 29:1995;215-220.
39. Bíró E., Toth G., Telegdy G. Effect of receptor blockers on brain natriuretic peptide and C-type natriuretic peptide caused anxiolytic state in rats. Neuropeptides. 30:1996;59-65.
40. Bíró E., Penke B., Telegdy G. Role of different neurotransmitter systems in the cholecystokinin octapeptide-induced anxiogenic response in rats. Neuropeptides. 31:1997;281-285.
41. Blanchard D.C., Blanchard R.J., Rodgers R.J. Risk assessment and animal models of anxiety. Olivier B., Mos J., Slangen J.L. Animal Models in Psychopharmacology. 1991;117-134 Birkhauser Verlag AG, Basel.
42. Boden P.R., Woodruff G.N., Pinnock R.D. Pharmacology of a cholecystokinin receptor on 5-hydroxytryptamine neurones in the dorsal raphe of the rat brain. Br. J. Pharmacol. 102:1991;635-638.
43. Bonaz B., Taché Y. Water-avoidance stress-induced c-fos expression in the rat brain and stimulation of fecal output. role of corticotropin-releasing factor Brain Res. 641:1994;21-28.
44. Boulenger J.P., Jerabek I., Jolicoeur F.B., Lavallee Y.J., Leduc R., Cadieux A. Elevated plasma levels of neuropeptide Y in patients with panic disorder. Am. J. Psychiatry. 153:1996;114-116.
45. Bourin M., Malinge M., Vasar E., Bradwejn J. Two faces of cholecystokinin. anxiety and schizophrenia Fundam. Clin. Pharmacol. 10:1996;116-126.
46. Britton D.R., Indyk E. Central effects of corticotropin releasing factor (CRF). evidence for similar interactions with environmental novelty and with caffeine Psychopharmacology. 101:1990;366-370.
47. Britton D.R., Koob G.F., Rivier J., Vale W. Intraventricular corticotrophin-releasing factor enhances behavioral effects of novelty. Life Sci. 31:1982;363-367.
48. Britton D.R., Varela M., Garcia A., Rivier J. Behavioral effects of intracerebral ventricular oCRF are independent of effects at the pituitary. Soc. Neurosci. Abstr. 10:1984;178.
49. Britton D.R., Varela M., Garcia A., Rivier J. Dexamethasone suppresses pituitary-adrenal but not behavioral effects of centrally administered CRF. Life Sci. 38:1986;211-216.
50. Britton K.T., Morgan J., Rivier J., Vale W., Koob G.F. Chlordiazepoxide attenuates response suppression induced by corticotropin-releasing factor in the conflict test. Psychopharmacology. 86:1985;170-174.
51. Britton K.T., Lee G., Dana R., Risch S.C., Koob G.F. Activating and "anxiogenic" effects of corticotropin releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasone. Life Sci. 39:1986;1281-1286. a.
52. Britton K.T., Lee G., Vale W., Rivier J., Koob G.F. Corticotropin releasing factor (CRF) receptor antagonist blocks activating and "anxiogenic" actions of CRF in the rat. Brain Res. 369:1986;303-306. b.
53. Britton K.T., Lee G., Koob G.F. Corticotropin releasing factor and amphetamine exaggerate partial agonist properties of benzodiazepine antagonist Ro 15-1788 in the conflict test. Psychopharmacology. 94:1988;306-311.
54. Britton K.T., McLeod S., Koob G.F., Hauger R. Pregnane steroid alphaxalone attenuates anxiogenic behavioral effects of corticotropin releasing factor and stress. Pharmacol. Biochem. Behav. 41:1992;399-403.
55. Britton K.T., Akwa Y., Southerland S., Koob G.F. Neuropeptide Y blocks the "anxiogenic-like" behavioral action of corticotropin-releasing factor. Soc. Neurosci. Abstr. 23:1997;521. a.
56. Britton K.T., Southerland S., VanUden E., Kirby D., Rivier J., Koob G. Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology. 132:1997;6-13. b.
57. Broqua P., Wettstein J.G., Gauthier-Martin B., Junien J.L. Evaluation of the behavioral effects of peptides related to neuropeptide Y. Neuropeptides. 26:1994;16.
58. Broqua P., Wettstein J.G., Rocher M.N., Gauthiermartin B., Junien J.L. Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav. Pharmacol. 6:1995;215-222.
59. Bueno L., Fioramonti J. Effects of corticotropin-releasing factor, corticotropin and cortisol on gastrointestinal motility in dogs. Peptides. 7:1986;73-77.
60. Bueno L., Gué M. Evidence for the involvement of corticotropin-releasing factor in the gastrointestinal disturbances induced by acoustic and cold stress in mice. Brain Res. 441:1988;1-4.
61. B receptor blockade J. Psychopharmacol. 11:1997;A9.
62. Butler P.D., Weiss J.M., Stout J.C., Nemeroff C.B. Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. J. Neurosci. 10:1990;176-183.
63. Buwalda B., Deboer S.F., VanKalkeren A.A., Koolhaas J.M. Physiological and behavioral effects of chronic intracerebroventricular infusion of corticotropin-releasing factor in the rat. Psychoneuroendocrinology. 22:1997;297-309.
64. 1 receptor mRNA expression J. Neurosci. 15:1995;6340-6350.
65. Charrier D., Dangoumau L., Puech A.J., Hamon M., Thiébot M.H. Failure of CCK receptor ligands to modify anxiety related behavioural suppression in an operant conflict paradigm in rats. Psychopharmacology. 121:1995;127-134.
66. 1 receptor antagonist J. Med. Chem. 40:1997;1749-1754.
67. Chopin P., Briley M. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Psychopharmacology. 110:1993;409-414.
68. Christos T.E., Arvanitis A. Corticotrophin-releasing factor receptor antagonists. Expert Opin. Ther. Patents. 8:1998;143-152.
69. Cole B.J., Koob G.F. Propranolol antagonizes the enhanced conditioned fear produced by corticotropin releasing factor. J. Pharmacol. Exp. Ther. 247:1988;902-910.
70. Cole B.J., Britton K.T., Koob G.F. Central administration of alpha-helical corticotropin-releasing factor attenuates the acquisition of a conditioned emotional response. Soc. Neurosci. Abstr. 13:1987;427.
71. 9-41. Pharmacol. Biochem. Behav. 48:1994;497-503.
72. 4 receptor antagonists to modify drug induced disinhibitory effects in the mouse light/dark test. Br. J. Pharmacol. 122:1997;1105-1118.
73. B antagonists. Neuropeptides. 19(Suppl.):1991;65-73.
74. Crawley J.N., Stivers J.A., Hommer D.W., Skirboll L.R., Paul S.M. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide. J. Pharmacol. Exp. Ther. 236:1986;320-330.
75. Csonka E., Fekete M., Nagy G., Szanto-Fekete M., Telegdy G. Anxiogenic effect of cholecystokinin in rats. Penke B., Toroke A. Peptides, Chemistry, Biology, Interactions with Proteins. 1988;249-252 Walter de Gruyter, Berlin.
76. Cutler M. Potential anxiolytic activity in gerbils from the substance P (SP) receptor antagonist, CGP 49823. J. Psychopharmacol. 8(Suppl.):1994;A22.
77. Daugé V., Roques B.P. Opioid and CCK systems in anxiety and reward. Bradwejn J., Vasar E. Cholecystokinin and Anxiety. from Neuron to Behavior:1995;152-171 R. G. Landes Company, Georgetown.
78. 8 injected into the medial nucleus accumbens are dependent on the motivational state of the rat. Eur. J. Pharmacol. 163:1989;25-32. a.
79. A receptors of the postero-median part of the nucleus accumbens. Pharmacol. Biochem. Behav. 34:1989;157-163. b.
80. B receptors by using a new highly potent CCK analog, BC 264. Synapse. 6:1990;73-80.
81. Dawbarn D., Hunt S.P., Emson P.C. Neuropeptide Y. regional distribution, chromatographic characterization and immunohistochemical demonstration in post-mortem human brain Brain Res. 296:1984;168-173.
82. De Boer S.F., Katz J.L., Valentino R.J. Common mechanisms underlying the proconflict effects of corticotropin-releasing factor, a benzodiazepine inverse agonist and electric foot-shock. J. Pharmacol. Exp. Ther. 262:1992;335-342.
83. Della-Fera M.A., Baile C.A. Cholecystokinin octapeptide. continuous picomole injections into the cerebral ventricles of sheep suppress feeding Science. 206:1979;471-473.
84. De Lima T.C.M., Ribeiro S.J. Central effects of tachykinin NK receptor agonists and antagonists on the plus-maze behavior in rats. Soc. Neurosci. Abstr. 22:1996;1154.
85. De Lima T.C.M., Teixeira R.M., Santos A.R.S., Rae G.A., Calixto J.B. Behavioral effects of intracerebroventricular injection of selective tachykinin agonists and antagonists. Soc. Neurosci. Abstr. 21:1995;1696.
86. De Lima, T. C. M., Baretta, I. P. and Assreuy, J. (1997) Nitric oxide involvement in the anxiogenic effect of substance P in mice in the elevated plus-maze. Soc. Neurosci. Abstr. 23: 1859.
87. Denenberg V.H. Open-field behavior in the rat. what does it mean? Ann. NY Acad. Sci. 159:1969;852-859.
88. Derrien M., McCort-Tranchepain I., Ducos B., Roques B.P., Durieux C. Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol. Biochem. Behav. 49:1994;133-141.
89. De Souza E.B. Corticotropin-releasing factor receptors. physiology, pharmacology, biochemistry and role in central nervous system and immune disorders Psychoneuroendocrinology. 20:1995;789-819.
90. De Weerth A., Pisegna J.R., Huppi K., Wank S.A. Molecular cloning, functional expression and chromosomal localization of the human cholecystokinin type A receptor. Biochem. Biophys. Res. Commun. 194:1993;811-818.
91. Dockray G.J. Immunochemical evidence of cholecystokinin-like peptides in brain. Nature. 264:1976;568-570.
92. B receptor antagonists in the CER and elevated zero maze models of anxiety in the rat. modulation by 5-HT reuptake blockade Behav. Pharmacol. 5:1994;29.
93. 2 radioligands. J. Pharmacol. Exp. Ther. 272:1995;673-680.
94. Dunn A.J., Berridge C.W. Corticotropin-releasing factor administration elicits a stress-like activation of cerebral catecholaminergic systems. Pharmacol. Biochem. Behav. 27:1987;685-691.
95. Dunn A.J., File S.E. Corticotropin-releasing factor has an anxiogenic action in the social interaction test. Horm. Behav. 21:1987;193-202.
96. B receptor agonist pentagastrin on feeding and cortisol release in sheep. Methods Fund. Exp. Clin. Pharmacol. 18:1996;235-238.
97. 2) receptor. Life Sci. 50: PL-101-PL-106.
98. Elkabir D.R., Wyatt M.E., Vellucci S.V., Herbert J. The effects of separate or combined infusions of corticotrophin-releasing factor and vasopressin either intraventricularly or into the amygdala on aggressive and investigative behaviour in the rat. Regul. Pept. 28:1990;199-214.
99. Emson P.C., Rehfeld J.F., Rossor M.N. Distribution of cholecystokinin-like peptides in the human-brain. J. Neurochem. 38:1982;1177-1179.
100. Erspamer V., Mechiorri P. Active polypeptides from amphibian skin to gastrointestinal tract and brain of mammals. Trends Pharmacol. Sci. 1:1980;3191.
101. Eysselein V.E., Reeve J.R. Jr., Eberlein G. Cholecystokinin - gene structure, and molecular forms in tissue and blood. Z. Gastroenterol. 24:1986;645-659.
102. Fendt M., Koch M., Kungel M., Schnitzler H.U. Cholecystokinin enhances the acoustic startle response in rats. Neuroreport. 6:1995;2081-2084.
103. Fendt M., Koch M., Schnitzler H.U. Corticotropin-releasing factor in the caudal pontine reticular nucleus mediates the expression of fear-potentiated startle in the rat. Eur. J. Neurosci. 9:1997;299-305.
104. B receptor antagonist CI-988. Br. J. Pharmacol. 102:1991;256P.
105. 1 receptor antagonist in the social interaction test. Pharmacol. Biochem. Behav. 58:1997;747-752.
106. File S.E., Johnston A.L., Baldwin H.A. Anxiolytic and anxiogenic drugs. changes in behaviour and endocrine responses Stress Med. 4:1988;221-230.
107. Fink H., Rex A., Marsden C.A. Behavioural and neurochemical effects of CCK-fragments in animal models of anxiety. Behav. Pharmacol. 5:1994;30.
108. Fontana D.J., Commissaris R.L. Effects of acute and chronic imipramine administration on conflict behavior in the rat. a potential "animal model" for the study of panic disorder? Psychopharmacology. 95:1988;147-150.
109. Fontana D.J., Carbary T.J., Commissaris R.L. Effects of acute and chronic anti-panic drug administration on conflict behavior in the rat. Psychopharmacology. 98:1989;157-162.
110. B receptor agonist pentagastrin potentiates acoustic startle. Brain Res. 733:1996;129-132.
111. B receptors potentiates the acoustic startle response in the rat. J. Neurosci. 17:1997;1838-1847.
112. Fulton B., Brogden R.N. Buspirone. an updated review of its clinical pharmacology and therapeutic applications CNS Drugs. 7:1997;68-88.
113. Fuxe K., Andersson K., Locatelli V., Agnati L.F., Hokfelt T., Skirboll L., Mutt V. Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection. Eur. J. Pharmacol. 67:1980;329-331.
114. Gacsalyi I., Schmidt E., Gyertyan I., Vasar E., Lang A., Haapalinna A., Fekete M., Hietala J., Syvalahti E., Tuomainen P., Mannisto P.T. Receptor binding profile and anxiolytic-type activity of deramciclane (EGIS-3886) in animal models. Drug Dev. Res. 40:1997;333-348.
115. Glover V., Bhattacharya S.K., Sandler M. Isatin - a new biological factor. Indian J. Exp. Biol. 29:1991;1-5.
116. Glover V., Medvedev A., Sandler M. Isatin is a potent endogenous antagonist of guanylate cyclase-coupled atrial natriuretic peptide receptors. Life Sci. 57:1995;2073-2079.
117. 9-41 on the sleep/waking cycle in rats under normal conditions or after subjection to an acute stressful stimulus. J. Sleep Res. 6:1997;164-170.
118. Graeff F.G. Neurotransmitters in the dorsal periaqueductal grey and animal models of panic anxiety. Briley M., File S.E. New Concepts in Anxiety. 1991;288-307 CRC Press, New York.
119. Gray T.S., Morley J.E. Neuropeptide Y. anatomical distribution and possible function in mammalian nervous system Life Sci. 38:1986;389-401.
120. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders. more than 30 years of research Pharmacol. Ther. 65:1995;319-395.
121. Griebel G. Serotonergic drugs in animal models of anxiety. an update Serotonin ID Res. Alert. 2:1997;251-257.
122. Griebel G., Blanchard D.C., Blanchard R.J. Predator-elicited flight responses in Swiss-Webster an experimental model of panic attacks. Prog. Neuropsychopharmacol Biol. Psych. 20:1996;185-205.
123. Griebel G., Perrault G., Sanger D.J. CCK receptor antagonists in animal models of anxiety. comparison between exploration tests, conflict procedures and a model based on defensive behaviours Behav. Pharmacol. 8:1997;549-560. a.
124. Griebel G., Rodgers R.J., Perrault G., Sanger D.J. Risk assessment behaviour. evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test Pharmacol. Biochem. Behav. 57:1997;817-827. b.
125. Griebel G., Perrault G., Sanger D.J. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology. 138:1998;55-66.
126. Guanowsky V., Seymour P.A. Effects of CRH and restraint stress in the light/dark anxiety test in mice. Soc. Neurosci. Abstr. 19:1993;2.
127. Guanowsky V., Chen Y.L., Seymour P.A. Anxiolytic effect of the CRF antagonist, CP-154,526, in a light/dark anxiety test in mice. Soc. Neurosci. Abstr. 23:1997;522.
128. Gué M., Junien J.L., Bueno L. Conditioned emotional response in rats enhances colonic motility through the central release of corticotropin-releasing factor. Gastroenterology. 100:1991;964-970.
129. Guimaraes F.S., Russo A.S., de Aguiar J.C., Ballejo G., Graeff F.G. Anxiogenic-like effect of CCK-8 micro-injected into the dorsal periaqueductal grey of rats in the elevated plus maze. Cooper S.J., Iversen S.D., Iversen L.L. Multiple Cholecystokinin Receptors in the CNS. 1992;149-154 Oxford University Press, Oxford.
130. Hagiwara M., Debas H., Taché Y. Inhibitory effects of corticotropin-releasing factor (CRF) on gastric emptying in rats. Gastroenterology. 90:1986;1447.
131. Harro J., Vasar E., Bradwejn J. CCK in animal and human research on anxiety. Trends. Pharmacol. Sci. 14:1993;244-249.
132. Harro J., Oreland L., Vasar E., Bradwejn J. Impaired exploratory behaviour after DSP-4 treatment in rats. implications for the increased anxiety after noradrenergic denervation Eur. Neuropsychopharmacol. 5:1995;447-455.
133. Hasenöhrl R.U., Jentiens O., De Souza Silva M.A., Tomaz C., Huston J.P. Anxiolytic action of substance P administered systemically or into the basal forebrain. Soc. Neurosci. Abstr. 22:1996;1152.
134. Heilig M. Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Regul. Pept. 59:1995;201-205.
135. Heilig M., Murison R. Intracerebroventricular neuropeptide Y protects against stress-induced gastric erosion in the rat. Eur. J. Pharmacol. 137:1987;127-129. a.
136. Heilig M., Murison R. Intracerebroventricular neuropeptide Y suppresses open field and home activity in the rat. Regul. Pept. 19:1987;221-231. b.
137. Heilig M., Soderpalm B., Engel J.A., Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology. 98:1989;524-529.
138. Heilig M., McLeod S., Koob G.K., Britton K.T. Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul. Pept. 41:1992;61-69.
139. 1 receptors in amygdala, and dissociation from food intake effects Neuropsychopharmacology. 8:1993;357-363.
140. Heinrichs S.C., Pich E.M., Miczek K.A., Britton K.T., Koob G.F. Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res. 581:1992;190-197.
141. 2, receptors mediate anxiogenic-like behavior. Regul. Pept. 71:1997;15-21.
142. Helton D.R., Berger J.E., Czachura J.F., Rasmussen K., Kallman M.J. Central nervous system characterization of the new cholecystokinin, antagonist LY288513. Pharmacol. Biochem. Behav. 53:1996;493-502.
143. Hendrie C.A., Dourish C.T. Anxiolytic profile of the cholecystokinin antagonist devazepide in mice. Br. J. Pharmacol. 99:1990;138P.
144. Hendrie C.A., Neill J.C. An animal model of panic disorder. J. Psychopharmacol. 6:1991;125.
145. Hendrie C.A., Weiss S.M. The effects of cholecystokinin antagonists in a novel model of panic in mice. Behav. Pharmacol. 5:1994;30.
146. B antagonists on activity in the black/white exploration model of anxiety in mice. Physiol. Behav. 54:1993;689-693.
147. Hennessy M.B., Becker L.A., O'Neil D.R. Peripherally administered CRH suppresses the vocalizations of isolated guinea pig pups. Physiol. Behav. 50:1991;17-22.
148. Hennessy M.B., O'Neil D.R., Becker L.A., Jenkins R., Williams M.T., Davis H.N. Effects of centrally administered corticotropin-releasing factor (CRF) and α-helical CRF on the vocalizations of isolated guinea pig pups. Pharmacol. Biochem. Behav. 43:1992;37-43.
149. Hennessy M.B., Long S.J., Nigh C.K., Williams M.T., Nolan D.J. Effects of peripherally administered corticotropin-releasing factor (CRF) and a CRF antagonist. does peripheral CRF activity mediate behavior of guinea pig pups during isolation? Behav. Neurosci. 109:1995;1137-1145.
150. Hennessy M.B., McInturf S.M., Mazzei S.J. Evidence that endogenous corticotropin-releasing factor suppresses behavioral responses of guinea pig pups to brief isolation in novel surroundings. Dev. Psychobiol. 31:1997;39-47.
151. Herman J.P., Langub M.C. Jr., Watson R.E. Jr. Localization of C-type natriuretic peptide mRNA in rat hypothalamus. Endocrinology. 133:1993;1903-1906.
152. Hernandez J.F., Kornreich W., Rivier C., Miranda A., Yamamoto G., Andrews J., Taché Y., Vale W., Rivier J. Synthesis and relative potencies of new constrained CRF antagonists. J. Med. Chem. 36:1993;2860-2867.
153. Herzog H., Hort Y.J., Ball H.J., Hayes G., Shine J., Selbie L.A. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc. Natl. Acad. Sci. USA. 89:1992;5794-5798.
154. Hinks G.L., Brown P., Field M., Poat J.A., Hughes J. The anxiolytics CI-988 and chlordiazepoxide fail to reduce immediate early gene mRNA stimulation following exposure to the rat-elevated X-maze. Eur. J. Pharmacol. 312:1996;153-161.
155. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 54:1996;21-30.
156. Hokfelt T., Skirboll L., Everitt B., Meister B., Brownstein M., Jacobs T., Faden A., Kuga S., Goldstein M., Markstein R. Distribution of cholecystokinin-like immunoreactivity in the nervous system. Co-existence with classical neurotransmitters and other neuropeptides. Ann. NY Acad. Sci. 448:1985;255-274.
157. Holahan M.R., Kalin N.H., Kelley A.E. Microinfusion of corticotropin-releasing factor into the nucleus accumbens shell results in increased behavioral arousal and oral motor activity. Psychopharmacology. 130:1997;189-196.
158. B ligands with anxiolytic-like properties. Bioorg. Med. Chem. Lett. 5:1995;3057-3062.
159. B antagonists with potent anxiolytic properties. J. Med. Chem. 34:1991;2304-2314.
160. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D.C., Hunter J.C., Pinnock R.D., Woodruff G.N. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. USA. 87:1990;6728-6732.
161. Hunt S.P., Emson P.C., Gilbert R., Goldstein M., Kimmell J.R. Presence of avian pancreatic polypeptide-like immunoreactivity in catecholamine and methionine-enkephalin-containing neurones within the central nervous system. Neurosci. Lett. 21:1981;125-130.
162. Huston J.P., Schildein S., Gerhardt P., Privou C., Fink H., Hasenohrl R.U. Modulation of memory, reinforcement and anxiety parameters by intra-amygdala injection of cholecystokinin-fragments Boc-CCK-4 and CCK-8s. Peptides. 19:1998;27-37.
163. Ichikawa T., McMaster D., Lederis K., Kobayashi H. Isolation and amino acid sequence of urotensin I, a vasoactive and ACTH-releasing neuropeptide, from the carp (Cyprinus carpio) urophysis. Peptides. 3:1982;859-867.
164. Imura H., Nakao K., Itoh H. The natriuretic peptide system in the brain. implications in the central control of cardiovascular and neuroendocrine functions Front. Neuroendocrinol. 13:1992;217-249.
165. Innis R.B., Snyder S.H. Distinct cholecystokinin receptors in brain and pancreas. Proc. Natl. Acad. Sci. USA. 77:1980;6917-6921.
166. Insel T.R., Harbaugh C.R. Central administration of corticotropin releasing factor alters rat pup isolation calls. Pharmacol. Biochem. Behav. 32:1989;197-201.
167. Ivy A.C., Oldberg E. Hormone mechanism for gallbladder contraction and evacuation. Am. J. Physiol. 86:1928;599-613.
168. B receptor antagonist LY288513 on conditioned fear stress in rats. Eur. J. Pharmacol. 300:1996;25-31.
169. Jenck F., Moreau J.L., Martin J.R. Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety. elements of face and predictive validity Psychiatry Res. 57:1995;181-191.
170. B receptor ligands in a validated simulation of panic anxiety in rats. Eur. Neuropsychopharmacol. 6:1996;291-298.
171. Jentiens O., Hasenöhrl R.U., De Souza Silva M.A., Tomaz C., Huston J.P. Anxiolytic-like effect of injecting neurokinin substance P systematically or into the basal forebrain. 2nd Meeting of European Neuroscience, Strasbourg, p. 197. 1996.
172. B) receptor ligands in the elevated plus-maze test of anxiety in mice. Psychopharmacology. 124:1996;355-364.
173. Jolkkonen J., Lepola U., Bissette G., Nemeroff C., Riekkinen P. CSF corticotropin-releasing factor is not affected in panic disorder. Biol. Psychiatry. 33:1993;136-138.
174. Jones D.N.C., Kortekaas R., Slade P.D., Hagan J.J. Comparison of behavioural effects of corticotropin-releasing factor and the novel neuropeptide, urocortin. Br. J. Pharmacol. 120(Suppl.):1997;363P.
175. B antagonist, L-365,260, attenuates fear-potentiated startle. Peptides. 16:1995;1313-1315. a.
176. B agonist, produces a facilitation of the acoustic startle reflex. Soc. Neurosci. Abstr. 21:1995;1697. b.
177. Kalin N.H. Behavioral effects of ovine corticotropin-releasing factor administered to rhesus monkeys. Fed. Proc. 44:1985;249-253.
178. Kalin N.H., Takahashi L.K. Fear-motivated behavior induced by prior shock experience is mediated by corticotropin-releasing hormone systems. Brain Res. 509:1990;80-84.
179. Kalin N.H., Shelton S.E., Kraemer G.W., McKinney W.T. Corticotropin-releasing factor administered intraventricularly to rhesus monkeys. Peptides. 4:1983;217-220.
180. Kalin N.H., Sherman J.E., Takahashi L.K. Antagonism of endogenous CRH systems attenuates stress-induced freezing behavior in rats. Brain Res. 457:1988;130-135.
181. Kask A., Rago L., Harro J. Anxiogenic-like effect of the neuropeptide Y Y-1 receptor antagonist BIBP3226. antagonism with diazepam Eur. J. Pharmacol. 317:1996;R3-R4.
182. Kask A., Rago L., Harro J. α-Helical CRF9-41 prevents anxiogenic-like effect of NPY Y-1 receptor antagonist BIBP3226 in rats. Neuroreport. 8:1997;3645-3647.
183. Kellner M., Wiedemann K., Holsboer F. Atrial natriuretic factor inhibits the CRH-stimulated secretion of ACTH and cortisol in man. Life Sci. 50:1992;1835-1842.
184. 1 receptor subclass J. Med. Chem. 38:1995;4579-4586.
185. A receptor gene knockout rats. Neurosci. Lett. 214:1996;61-64.
186. Koob G.F. Behavioral responses to stress - focus on corticotropin-releasing factor. Brown M.R., Koob G.F., Rivier C. Stress, Neurobiology and Neuroendocrinology. 1991;255-271 Marcel Dekker, New York.
187. Koob G.F., Gold L.H. Molecular biological approaches in the behavioural pharmacology of anxiety and depression. Behav. Pharmacol. 8:1997;652.
188. Korte S.M., Korte-Bouws G.A.H., Bohus B., Koob G.F. Effect of corticotropin-releasing factor antagonist on behavioral and neuroendocrine responses during exposure to defensive burying paradigm in rats. Physiol. Behav. 56:1994;115-120.
189. Krahn D.D., Gosnell B.A., Grace M., Levine A.S. CRF antagonist partially reverses CRF- and stress-induced effects on feeding. Brain Res. Bull. 17:1986;285-289.
190. Krahn D.D., Gosnell B.A., Levine A.S., Morley J.E. Behavioral effects of corticotropin-releasing factor. localization and characterization of central effects Brain Res. 443:1988;63-69.
191. B antagonist, in panic disorder. Biol. Psychiatry. 37:1995;462-466.
192. Kumar K.B., Karanth K.S. Alpha-helical CRF blocks differential influence of corticotropin releasing factor (CRF) on appetitive and aversive memory retrieval in rats. J. Neural Transm. 103:1996;1117-1126.
193. A Receptors and Anxiety. 1995;135-152 Raven Press, New York.
194. B agonist, BC264, increases dopamine in the nucleus accumbens and facilitates motivation and attention after intraperitoneal injection in rats. Eur. J. Neurosci. 9:1997;1804-1814.
195. Lang C.C., Choy A.M., Struthers A.D. Atrial and brain natriuretic peptides. a dual natriuretic peptide system potentially involved in circulatory homeostasis Clin. Sci. 83:1992;519-527.
196. 1 type. J. Biol. Chem. 267:1992;10935-10938.
197. 1A receptor agonists on CRF-induced behavior. Psychopharmacology. 104:1991;132-136.
198. Lederis K., Letter A., McMaster D., Ichikawa T., MacCannell K.L., Kobayashi Y., Rivier J., Rivier C., Vale W., Fryer J. Isolation, analysis of structure, synthesis, and biological actions of urotensin I neuropeptides. Can. J. Biochem. Cell Biol. 61:1983;602-614.
199. Lee E.H., Tsai M.J. The hippocampus and amygdala mediate the locomotor stimulating effects of corticotropin-releasing factor in mice. Behav. Neural Biol. 51:1989;412-423.
200. Lee E.H., Tang Y.P., Chai C.Y. Stress and corticotropin-releasing factor potentiate center region activity of mice in an open field. Psychopharmacology. 93:1987;320-323.
201. Lee Y., Davis M. Role of the bed nucleus of the stria terminalis and the amygdala in the excitatory effect of CRH on the acoustic startle reflex. Soc. Neurosci. Abstr. 21:1995;1697.
202. Lee Y.L., Davis M. Role of the septum in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex. J. Neurosci. 17:1997;6424-6433. a.
203. Lee Y.L., Davis M. Role of the hippocampus, the bed nucleus of the stria terminalis, and the amygdala in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex. J. Neurosci. 17:1997;6434-6446. b.
204. Lenz H.J., Burlage M., Raedler A., Greten H. Central nervous system effects of corticotropin-releasing factor on gastrointestinal transit in the rat. Gastroenterology. 94:1988;598-602. a.
205. Lenz H.J., Raedler A., Greten H., Vale W.W., Rivier J.E. Stress-induced gastrointestinal secretory and motor responses in rats are mediated by endogenous corticotropin-releasing factor. Gastroenterology. 95:1988;1510-1517. b.
206. Liang K.C., Lee E.H. Intra-amygdala injections of corticotropin releasing factor facilitate inhibitory avoidance learning and reduce exploratory behavior in rats. Psychopharmacology. 96:1988;232-236.
207. Liang K.C., Melia K.R., Campeau S., Falls W.A., Miserendino M.J., Davis M. Lesions of the central nucleus of the amygdala, but not the paraventricular nucleus of the hypothalamus, block the excitatory effects of corticotropin-releasing factor on the acoustic startle reflex. J. Neurosci. 12:1992;2313-2320. a.
208. Liang K.C., Melia K.R., Miserendino M.J., Falls W.A., Campeau S., Davis M. Corticotropin-releasing factor. long-lasting facilitation of the acoustic startle reflex J. Neurosci. 12:1992;2303-2312. b.
209. 1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul. Pept. 59:1995;229-239.
210. 2β receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology. 136:1995;4139-4142.
211. Lundberg J.M., Franco Cereceda A., Lacroix J.S., Pernow J. Neuropeptide Y and sympathetic neurotransmission. Ann. NY Acad. Sci. 611:1990;166-174.
212. Lundkvist J., Chai Z., Teheranian R., Hasanvan H., Bartfai T., Jenck F., Widmer U., Moreau J.L. A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur. J. Pharmacol. 309:1996;195-200.
213. MacNeil G., Sela Y., McIntosh J., Zacharko R.M. Anxiogenic behavior in the light-dark paradigm following intraventricular administration of cholecystokinin-8S, restraint stress, or uncontrollable footshock in the CD-1 mouse. Pharmacol. Biochem. Behav. 58:1997;737-746.
214. Maggi C.A. The mammalian tachykinin receptors. Gen. Pharmacol. 26:1995;911-944.
215. B receptors in behavioural and hormonal studies in rats. Naunyn Schmiedebergs Arch. Pharmacol. 349:1994;478-484.
216. Martin P. Effects of anxiolytic and antidepressant drugs in an animal model of panic. Hamon M., Ollat H., Thiébot M.H. Anxiety. Neurobiology, Clinic and Therapeutic Perspectives:1993;203-204 Les éditions INSERM/John Libbey Eurotext Ltd, Paris.
217. Martinez V., Rivier J., Wang L.X., Taché Y. Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function. J. Pharmacol. Exp. Ther. 280:1997;754-760.
218. Martins A.P., Marras R.A., Guimaraes F.S. Anxiogenic effect of corticotropin-releasing hormone in the dorsal periaqueductal grey. Neuroreport. 8:1997;3601-3604.
219. Matto V., Harro J., Allikmets L. The effect of drugs acting on CCK receptors and rat free exploration in the exploration box. J. Physiol. Pharmacol. 48:1997;239-251. a.
220. Matto V., Harro J., Allikmets L. The effects of cholecystokinin A and B receptor antagonists on exploratory behaviour in the elevated zero-maze in rat. Neuropharmacology. 36:1997;389-396. b.
221. McInturf S.M., Hennessy M.B. Peripheral administration of a corticotropin-releasing factor antagonist increases the vocalizing and locomotor activity of isolated guinea pig pups. Physiol. Behav. 60:1996;707-710.
222. McKay D.W., Adamec R. The effects of CRF and α-helical CRF on anxiety in normal and hypophysectomized rats. Soc. Neurosci. Abstr. 19:1993;373.
223. McMaster D., Rivier J., Lederis K. Isolation, amino acid sequence and synthesis of urotensin I from Hippoglossoides elassodon. Shiba T., Sakakibara S. Peptide Chemistry 1987. 1988;145-148 Protein Research Foundation, Osaka.
224. Menzaghi F., Heinrichs S.C., Merlo Pich E., Tilders F.J.H., Koob G.F. Attenuation of endocrine and behavioral responses to social conflict stress in rats by microinjection of cytotoxic antibody to corticotropin releasing factor and Ricin A chain toxin within the paraventricular nuclei. Soc. Neurosci. Abstr. 18:1992;535.
225. Menzaghi F., Howard R.L., Heinrichs S.C., Vale W., Rivier J., Koob G.F. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J. Pharmacol. Exp. Ther. 269:1994;564-572.
226. Miczek K.A. Genetic approaches to anxiety and depression. Behav. Pharmacol. 8:1997;657-658.
227. Mills S.G. Recent advances in neurokinin receptor antagonists. Annu. Rep. Med. Chem. 32:1997;51-60.
228. Molewijk H.E., Vanderpoel A.M., Mos J., Vanderheyden J.A.M., Olivier B. Conditioned ultrasonic distress vocalizations in adult male rats as a behavioural paradigm for screening anti-panic drugs. Psychopharmacology. 117:1995;32-40.
229. Mongeau R., Marsden C.A. Effect of central and peripheral administrations of cholecystokinin-tetrapeptide on panic-like reactions induced by stimulation of the dorsal periaqueductal grey area in the rat. Biol. Psychiatry. 42:1997;335-344.
230. Mönnikes H., Schmidt B.G., Raybould H.E., Taché Y. CRF in the paraventricular nucleus mediates gastric and colonic motor response to restraint stress. Am. J. Physiol. 262:1992;G137-G143. a.
231. Mönnikes H., Schmidt B.G., Taché Y. Corticotropin releasing factor (CRF) microinfused into the locus coeruleus complex (LCC) stimulates colonic transit in the conscious rat. Gastroenterology. 102:1992;A488. b.
232. Mönnikes H., Schmidt B.G., Taché Y. Psychological stress-induced accelerated colonic transit in rats involves hypothalamic corticotropin-releasing factor. Gastroenterology. 104:1993;716-723.
233. Moran T.H., Robinson P.H., Goldrich M.S., McHugh P.R. Two brain cholecystokinin receptors. implications for behavioral actions Brain Res. 362:1986;175-179.
234. Moreau J.L., Kilpatrick G., Jenck F. Urocortin, a novel neuropeptide with anxiogenic-like properties. Neuroreport. 8:1997;1697-1701.
235. Morimoto A., Nakamori T., Morimoto K., Tan N., Murakami N. The central role of corticotrophin-releasing factor (CRF-41) in psychological stress in rats. J. Physiol. 460:1993;221-229.
236. Morley J.E., Levine A.S. Corticotrophin releasing factor, grooming and ingestive behavior. Life Sci. 31:1982;1459-1464.
237. Moy S.S., Knapp D.J., Criswell H.E., Breese G.R. Flumazenil blockade of anxiety following ethanol withdrawal in rats. Psychopharmacology. 131:1997;354-360.
238. Mutt V., Jorpes E. Hormonal polypeptides of the upper intestine. Biochem. J. 125:1971;57P-58P.
239. Nakajima M., Inui A., Asakawa A., Momose K., Ueno N., Teranishi A., Baba S., Kasuga M. Neuropeptide Y produces anxiety via Y2-type receptors. Peptides. 19:1998;359-363.
240. Nicholls M.G. Minisymposium. the natriuretic peptide hormones. Introduction. Editorial and historical review J. Intern. Med. 235:1994;507-514.
241. Orth D.N. Corticotropin-releasing hormone in humans. Endocr. Rev. 13:1992;164-191.
242. Otsuka M., Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. 73:1993;229-308.
243. Palit G., Kumar R., Patnaik G.K., Bhattacharya S.K. Behavioural effects of isatin, a putative biological factor, in rhesus monkeys. Biog. Amine. 13:1997;131-142.
244. B antagonist LY262691. Soc. Neurosci. Abstr. 17:1991;1602.
245. 4 in monkeys are reduced by CCK-B antagonists, benzodiazepines or adenosine A2 agonists. Eur. Neuropsychopharmacol. 2:1992;193-195.
246. Pande A.C. Lack of efficacy of a cholecystokinin-B antagonist in anxiety disorders. Biol. Psychiatry. 42:1997;11-19.
247. Panksepp J., Normansell L., Bishop B.H.P., Crepeau L. Neural and neurochemical control of the separation distress call. Newman J.D. The Physiological Control of Mammalian Vocalization. 1988;263-299 Plenum Press, New York.
248. Pavlasevic S., Bednar I., Qureshi G.A., Södersten P. Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety. Neuroreport. 5:1993;225-228.
249. Pelton G.H., Lee Y.L., Davis M. Repeated stress, like vasopressin, sensitizes the excitatory effects of corticotropin releasing factor on the acoustic startle reflex. Brain Res. 778:1997;381-387.
250. Pernow J., Schwieler J., Kahan T., Hjemdahl P., Oberle J., Wallin B.G., Lundberg J.M. Influence of sympathetic discharge pattern on norepinephrine and neuropeptide Y release. Am. J. Physiol. 257:1989;H866-H872.
251. Pisegna J.R., de Weerth A., Huppi K., Wank S.A. Molecular cloning of the human brain and gastric cholecystokinin receptor. structure, functional expression and chromosomal localization Biochem. Biophys. Res. Commun. 189:1992;296-303.
252. Poggioli R., Vergoni A.V., Rasori E., Marrama D., Bertolini A. Behavioral effects of atriopeptin in rats. Neuropeptides. 22:1992;149-154.
253. B antagonist, on the punished responding of squirrel monkeys. Neuropeptides. 19(Suppl.):1991;75-78.
254. Ramos A., Mormede P. Stress and emotionality. a multidimensional and genetic approach Neurosci. Biobehav. Rev. 22:1998;33-57.
255. Rasmussen K., Helton D.R., Berger J.E., Scearce E. The CCK-B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle. Neuroreport. 5:1993;154-156.
256. B antagonist LY288513 blocks the effects of nicotine withdrawal on auditory startle. Neuroreport. 7:1996;1050-1052.
257. Rassnick S., Heinrichs S.C., Britton K.T., Koob G.F. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res. 605:1993;25-32.
258. Rataud J., Darche F., Piot O., Stutzmann J.M., Bohme G.A., Blanchard J.C. "Anxiolytic" effect of CCK-antagonists on plus-maze behavior in mice. Brain Res. 548:1991;315-317.
259. Ravard S., Dourish C.T., Iversen S.D. Evidence that the anxiolytic-like effects of the CCK antagonists devazepide and L-365,260 in the elevated plus-maze paradigm in rats are mediated by CCK receptors. Br. J. Pharmacol. 101:1990;576P.
260. Regoli D., Boudon A., Fauchere J.L. Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. 46:1994;551-599.
261. Rex A., Barth T., Voigt J.-P., Domeney A.M., Fink H. Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety. Neurosci. Lett. 172:1994;139-142. a.
262. Rex A., Fink H., Marsden C.A. Effects of BOC-CCK-4 and L 365.260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus maze. Neuropharmacology. 33:1994;559-565. b.
263. Rex A., Marsden C.A., Fink H. Cortical 5-HT-CCK interactions and anxiety-related behaviour of guinea-pigs. a microdialysis study Neurosci. Lett. 228:1997;79-82.
264. Rivier C., Rivier J., Lederis K., Vale W. In vitro and in vivo ACTH-releasing activity of ovine CRF, sauvagine and urotensin I. Regul. Pept. 5:1983;139-143.
265. Rodgers R.J. Animal models of "anxiety" where next? Behav. Pharmacol. 8:1997;477-496.
266. Rodgers R.J., Cole J.C. The elevated plus-maze. pharmacology, methodology and ethology Cooper S.J., Hendrie C.A. Ethology and Psychopharmacology. 1994;9-44 John Wiley & Sons, Chichester.
267. Rodriguez de Fonseca F., Rubio P., Menzaghi F., Merlo Pich E., Rivier J., Koob G.F., Navarro M. Corticotropin-releasing factor (CRF) antagonist (D-Phe12, Nle21, 38, C αMeLeu37)CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther. 276:1996;56-64.
268. 1 antagonists on social interaction in rats. Soc. Neurosci. Abstr. 22:1996;1544.
269. Rose P.M., Fernandes P., Lynch J.S., Frazier S.T., Fisher S.M., Kodukula K., Kienzle B., Seethala R. Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor. J. Biol. Chem. 270:1995;29038-29041.
270. Roy Byrne P.P., Uhde T.W., Post R.M., Gallucci W., Chrousos G.P., Gold P.W. The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am. J. Psychiatry. 143:1986;896-899.
271. Sandler M., Clow A., Watkins P.J., Glover V. Tribulin - an endocoid marker for anxiety in man. Stress Med. 4:1988;215-219.
272. Sarnyai Z., Bíró E., Gardi J., Vecsernyes M., Julesz J., Telegdy G. Brain corticotropin-releasing factor mediates "anxiety-like" behavior induced by cocaine withdrawal in rats. Brain Res. 675:1995;89-97.
273. Schulz D.W., Mansbach R.S., Sprouse J., Braselton J.P., Collins J., Corman M., Dunaiskis A., Faraci S., Schmidt A.W., Seeger T., Seymour P., Tingley F.D. III, Winston E.N., Chen Y.L., Heym J. CP-154,526. a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors Proc. Natl. Acad. Sci. USA. 93:1996;10477-10482.
274. Servant D. Role of corticotropin-releasing factor in anxiety. Biol. Psychiatry. 42:1997;60-65.
275. Sherman J.E., Kalin N.H. ICV-CRH potently affects behavior without altering antinociceptive responding. Life Sci. 39:1986;433-441.
276. Sherman J.E., Kalin N.H. The effects of ICV-CRH on novelty-induced behavior. Pharmacol. Biochem. Behav. 26:1987;699-703.
277. Sherman J.E., Kalin N.H. ICV-CRH alters stress-induced freezing behavior without affecting pain sensitivity. Pharmacol. Biochem. Behav. 30:1988;801-807.
278. Sherman J.E., Barksdale C.M., Takahashi L.K., Kalin N.H. Footshock-elicited freezing in the rat is enhanced by intra-cerebroventricular administration of corticotropin-releasing hormone and is attenuated by its antagonist. Soc. Neurosci. Abstr. 13:1987;427.
279. Sieghart W., Schuster A. Affinity of various ligands for benzodiazepine receptors in rat cerebellum and hippocampus. Pharmacol. Biochem. Behav. 33:1984;4033-4038.
280. B receptor antagonist. Br. J. Pharmacol. 104:1991;239-245. a.
281. B receptor agonist induces anxiety. Br. J. Pharmacol. 102:1991;45P. b.
282. Singh L., Lewis A.S., Field M.J., Hughes J., Woodruff G.N. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc. Natl. Acad. Sci. USA. 88:1991;1130-1133. c.
283. Singh L., Field M.J., Vass C.A., Hughes J., Woodruff G.N. The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988. Br. J. Pharmacol. 105:1992;8-10.
284. Skofitsch G., Jacobowitz D.M., Eskay R.L., Zamir N. Distribution of atrial natriuretic factor-like immunoreactive neurons in the rat brain. Neuroscience. 16:1985;917-948.
285. Skutella T., Criswell H., Moy S., Probst J.C., Breese G.R., Jirikowski G.F., Holsboer F. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide induces anxiolytic effects in rat. Neuroreport. 5:1994;2181-2185.
286. Smagin G.N., Harris R.B.S., Ryan D.H. Corticotropin-releasing factor receptor antagonist infused into the locus coeruleus attenuates immobilization stress-induced defensive withdrawal in rats. Neurosci. Lett. 220:1996;167-170.
287. Somogyi P., Hodgson A.J., Smith A.D., Nunzi M.G., Gorio A., Wu J.Y. Different populations of GABAergic neurons in the visual cortex and hippocampus of cat contain somatostatin- or cholecystokinin-immunoreactive material. J. Neurosci. 4:1984;2590-2603.
288. Spadaro F., Berridge C.W., Baldwin H.A., Dunn A.J. Corticotropin-releasing factor acts via a third ventricle site to reduce exploratory behavior in rats. Pharmacol. Biochem. Behav. 36:1990;305-309.
289. Spina M., Merlo Pich E., Chan R.K., Basso A.M., Rivier J., Vale W., Koob G.F. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science. 273:1996;1561-1564.
290. Spina M., Zorrilla E.P., Basso A.M., Balducci C., Merlo-Pich E., Rivier J., Vale W., Koob G.F. Comparison of behavioral effects of central urocortin or CRF infusion. Soc. Neurosci. Abstr. 23:1997;521.
291. Squires R.F., Benson D.I., Braestrup C., Coupet J., Klepner C.A., Myers V., Beer B. Some properties of brain specific benzodiazepine receptors. new evidence for multiple receptors Pharmacol. Biochem. Behav. 10:1979;825-830.
292. Stein M.B., Hauger R.L., Dhalla K.S., Chartier M.J., Asmundson G.J.G. Plasma neuropeptide Y in anxiety disorders. findings in panic disorder and social phobia Psychiatry Res. 59:1996;183-188.
293. Stenzel-Poore M.P., Duncan J.E., Rittenberg M.B., Bakke A.C., Heinrichs S.C. CRH overproduction in transgenic mice. behavioral and immune system modulation Ann. NY Acad. Sci. 780:1996;36-48.
294. Stout S.C., Kilts C.D., Nemeroff C.B. Neuropeptides and stress. preclinical findings and implications for pathophysiology Friedman M.J., Charney S., Deutch A.Y. Neurobiological and Clinical Consequences of Stress. From Normal Adaptation to Post-Traumatic Stress Disorder:1995;103-123 Lippencott-Raven, Philadelphia.
295. 2 receptor agonists and antagonists in rat models of anxiety. J. Psychopharmacol. 7(Suppl.):1993;A11. a.
296. 2 receptor antagonists in the mouse light-dark box. Eur. J. Pharmacol. 250:1993;R11-R12. b.
297. 2 receptor antagonist, releases suppressed behaviours in a novel aversive environment. Br. J. Pharmacol. 112(Suppl.):1994;49P.
298. Strohle A., Jahn H., Montkowski A., Liebsch G., Boll E., Landgraf R., Holsboer F., Wiedemann K. Central and peripheral administration of atriopeptin is anxiolytic in rats. Neuroendocrinology. 65:1997;210-215.
299. Sutton R.E., Koob G.F., le Moal M., Rivier J., Vale W. Corticotropin releasing factor (CRF) produces behavioral activation in rats. Nature. 297:1982;331-333.
300. Swerdlow N.R., Geyer M.A., Vale W.W., Koob G.F. Corticotropin-releasing factor (CRF) potentiates acoustic startle reflex (ASR) in rats. blockade by chlordiazepoxide Soc. Neurosci. Abstr. 11:1985;620.
301. Swerdlow N.R., Geyer M.A., Vale W.W., Koob G.F. Corticotropin-releasing factor potentiates acoustic startle in rats. blockade by chlordiazepoxide Psychopharmacology. 88:1986;147-152.
302. 9-41. Neuropsychopharmacology. 2:1989;285-292.
303. Swiergiel A.H., Takahashi L.K., Kalin N.H. Attenuation of stress-induced behavior by antagonism of corticotropin-releasing factor receptors in the central amygdala in the rat. Brain Res. 623:1993;229-234.
304. Takahashi L.K., Kalin N.H. Role of corticotropin-releasing factor in mediating the expression of defensive behavior. Brain P.F., Blanchard D.C., Parmigiani S. Ethoexperimental Approaches to the Study of Behavior, pp. 580-592. 1989;Kluwer Academic Publishers, Dordrecht. Blanchard.
305. Takahashi L.K., Kalin N.H., Vanden Burgt J.A., Sherman J.E. Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats. Behav. Neurosci. 103:1989;648-654.
306. Takahashi L.K., Kalin N.H., Baker E.W. Corticotropin-releasing factor antagonist attenuates defensive-withdrawal behavior elicited by odors of stressed conspecifics. Behav. Neurosci. 104:1990;386-389.
307. Tatemoto K., Carlquist M., Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature. 296:1982;659-660.
308. Tazi A., Dantzer R., le Moal M., Rivier J., Vale W., Koob G.F. Corticotropin-releasing factor antagonist blocks stress-induced fighting in rats. Regul. Pept. 18:1987;37-42.
309. Teixeira R.M., Santos A.R.S., Ribeiro S.J., Calixto J.B., Rae G.A., DeLima T.C.M. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur. J. Pharmacol. 311:1996;7-14.
310. Thatcher Britton K., Koob G.F. Alcohol reverses the proconflict effect of corticotropin-releasing factor. Regul. Pept. 16:1986;315-320.
311. Thatcher Britton K., Rivier J., Vale W., Koob G.F. Chlordiazepoxide attenuates CRF effects on conflict test. Soc. Neurosci. Abstr. 13:1987;1122.
312. B receptor activation and anxiogenic behavior. a neuroanatomical analysis Soc. Neurosci. Abstr. 23:1997;1621.
313. Vale W.W., Spiess J., Rivier C., Rivier J. Characterization of a 41 residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and β-endorphin. Science. 213:1981;1394-1397.
314. Vale W.W., Rivier C., Brown M.R., Spiess J., Koob G., Swanson L., Bilezikjian L., Bloom F., Rivier J. Chemical and biological characterization of corticotropin-releasing factor. Recent Prog. Horm. Res. 39:1983;245-270.
315. Van der Haegen J.J., Signeau J.C., Gepts W. New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature. 257:1975;604-605.
316. Van Megen H.J.G.M., Westenberg H.G.M., den Boer J.A., Kahn R.S. Cholecystokinin in anxiety. Eur. Neuropsychopharmacol. 6:1996;263-280.
317. Van Vliet I.M., Westenberg H.G.M., Slaap B.R., den Boer J.A., Pian K.L.H. Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls. Biol. Psychiatry. 42:1997;76-78.
318. Vasar E. CCK agonists and antagonists in animal models of anxiety. J. Psychopharmacol. 11(Suppl.):1997;A93.
319. Vasar E., Lang A., Harro J., Bourin M., Bradwejn J. Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze. Neuropharmacology. 33:1994;729-735. a.
320. B receptors upon the regulation of behaviour and hormonal secretion in rodents. Behav. Pharmacol. 5:1994;31. b.
321. Vasar E., Koks S., Volke V., Voikar V. Cholecystokinin in animal models of anxiety. Biol. Psychiatry. 42:1997;196S.
322. Vassout A., Schaub M., Gentsch C., Ofner S., Schilling W., Veenstra S. CGP 49823, a novel NK-1 receptor antagonist. behavioural effects Neuropeptides. 26(Suppl.):1994;38.
323. Veldhuis H.D., De Wied D. Differential behavioral actions of corticotropin-releasing factor (CRF). Pharmacol. Biochem. Behav. 21:1984;707-713.
324. Wahlestedt C., Reis D.J. Neuropeptide Y-related peptides and their receptors - are the receptors potential therapeutic drug targets? Annu. Rev. Pharmacol. Toxicol. 33:1993;309-352.
325. 1 receptors by antisense oligodeoxynucleotides. Science. 259:1993;528-531.
326. 2 receptor antagonist, in rodent and primate models of anxiety. Psychopharmacology. 121:1995;186-191.
327. Watkins P., Clow A., Glover V., Halket J., Przyborowska A., Sandler M. Isatin, regional distribution in rat brain and tissues. Neurochem. Int. 17:1990;321-323.
328. Weidemann K.A., Zeller K.L., Fetterman A.L., McElroy J.F. Comparison of a CRH receptor antagonist and known anxiolytic agents on defensive withdrawal and locomotor activity in rats. Soc. Neurosci. Abstr. 22:1996;1544.
329. Weiss J.M., Stout J.C., Aaron M.F., Quan N., Owens M.J., Butler P.D., Nemeroff C.B. Depression and anxiety. role of the locus coeruleus and corticotropin-releasing factor Brain Res. Bull. 35:1994;561-572.
330. Westenberg H.G.M. Developments in the drug treatment of panic disorder. what is the place of the selective serotonin reuptake inhibitors? J. Affect. Disord. 40:1996;85-93.
331. Wettstein J.G., Broqua P., Rocher M.N., Junien J.L. Attenuation of fear-potentiated startle by neuropeptide Y receptor agonists. Neuropeptides. 26:1994;16-17.
332. Widerlöv E., Lindstrom L.H., Wahlestedt C., Ekman R. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J. Psychiatr. Res. 22:1988;69-79.
333. Wiersma A., Bohus B., Koolhaas J.M. Corticotropin-releasing hormone microinfusion in the central amygdala enhances active behaviour responses in the conditioned defensive burying paradigm. Stress. 1:1996;113-122.
334. Wiersma A., Knollema S., Konsman J.P., Bohus B., Koolhaas J.M. Corticotropin-releasing hormone modulation of a conditioned stress response in the central amygdala of Roman high (RHA/Verh)-avoidance and low (RLA/Verh)-avoidance rats. Behav. Genet. 27:1997;547-555.
335. Wigle D.A., Bennett B.M., Jennings D.B., Sarda I.R., Flynn T.G., Pang S.C. Biological effects of rat iso-atrial natriuretic peptide and brain natriuretic peptide are indistinguishable from each other. Can. J. Physiol. Pharmacol. 70:1992;1525-1528.
336. Williams C.L., Peterson J.M., Villar R.G., Burks T.F.
337. Winslow J.T., Newman J.D., Insel T.R. CRH and α-helical-CRH modulate behavioral measures of arousal in monkeys. Pharmacol. Biochem. Behav. 32:1989;919-926.
338. Wu H.C., Chen K.Y., Lee W.Y., Lee E.H.Y. Antisense oligonucleotides to corticotropin-releasing factor impair memory retention and increase exploration in rats. Neuroscience. 78:1997;147-153.
339. Yang X.M., Dunn A.J. Central β1-adrenergic receptors are involved in CRF-induced defensive withdrawal. Pharmacol. Biochem. Behav. 36:1990;847-851.
340. Yang X.M., Gorman A.L., Dunn A.J. The involvement of central noradrenergic systems and corticotropin-releasing factor in defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther. 255:1990;1064-1070.
341. 1) receptor antagonist (+/-)-CP-96,345 causes sedation and motor impairment in Swiss albino mice in the black-and-white box behavioral paradigm. Neurosci. Lett. 143:1992;169-172.
342. 1) antagonists CP-96,345 and RP 67580 in Swiss albino mice in the black-and-white box. Neurosci. Lett. 151:1993;64-66.
343. Zhang L., Barrett J.E. Interactions of corticotropin-releasing factor with antidepressant and anxiolytic drugs. behavioral studies with pigeons Biol. Psychiatry. 27:1990;953-967.